DelveInsight Blogs Sitemap

All Posts in this category
S.No. Product Name Actions
1 Biogen-Eisai's Aduhelm; Quidel acquires Ortho Clinical Diagnostics; Accutar Biotechnology’s AC0176; Boehringer’s Spesolimab Visit Post
2 Sky Medical’s Geko™ device; Fist Assist Devices obtains Breakthrough Device designation; Edwards obtains FDA approval; BD launched instrument for testing; GE acquires BK Medical; Zynex’ CM-1500; Foldax’s TRIA biopolymer heart valve Visit Post
3 An in-depth Assessment of the Top Drugs Launched by Leading Global Companies in the First Half of 2021 (H1) Visit Post
4 FDA 510k clearance to Naviswiss's Naviplan; FDA approved to TYRVAYA; Centinel Spine's STALIF Integrated Interbody System; Smith+Nephew's IODOSORB; AlloSource's AlloMend Extra-Large ADM; SpinaFX and StarFish's strategic commercialisation contract Visit Post
5 Analyzing the Key Companies and the Emerging Gene Therapy in the Dermatology Segment Visit Post
6 Development of Gene Therapies in Dermatology Visit Post
7 Brickell to Submit New Drug Application to FDA; Twin Health Raises $140M; BMS' Deucravacitinib; Lando Biopharma’s LABP-104 gets Approval; NIH Grant of $ 3 M to Amydis; FDA Grant to GenSight’ GS030 Visit Post
8 UNION Therapeutics-Innovent's collaboration; Delix Therapeutics bags $ 70 M; Biohaven’s Verdiperstat clinical trial result; Intra-Cellular's CAPLYTA Phase III study Visit Post
9 Aelis Farma pockets $30M; Alcyone unveils $23M for AAV gene therapies; Progentec and GSK collaborate; Kozin bags $60M Visit Post
10 Pharma Companies Foray into the ABSSSI Market to Develop Novel Antibiotics and Tackle Antibiotic Resistance Visit Post
11 Vertex leads in CRISPR Therapeutics deal; Update for Phase 2 clinical trial of KVD824; Ovid dumps lead program; Virta Health pulls in $133M Visit Post
12 Merck, Gilead teams up for HIV treatment; Bright Future for Sanofi/Regeneron’s Libtayo; Roche acquires GenMark; FDA okays Melinta's Kimyrsa Visit Post
13 Beam makes USD 120M bet; GRAIL and Quest announce the collaboration; Brain organoids mimic infant’s brains; Improvement in T cells to kill cancer Visit Post
14 Plaque psoriasis drug outshines in phase III trial; Immunovant announces pause in trial of IMVT-1401; Prothena brings AL amyloidosis drug back; Canon Medical expands its MRI AI programs Visit Post
15 Horizon, Viela Deal; Concert Schizo Drug Flop; Gilead Deals with Arcus and Gritstone Visit Post
16 A Need for Curative Treatment Expected to Attract the Pharma Players in the Hallux Valgus Market Landscape Visit Post
17 Bristol Myers' psoriasis drug; GW Pharmaceuticals eyes US market for Nabiximols; Karyopharm's Xpovio; Kiadis USD 358M Buyout Visit Post
18 Pharma Players Line Up To Launch Novel Therapies Fueling Epidermolysis Bullosa Market Size Visit Post
19 Do We Have A Cure For Rosacea? Visit Post
20 Incyte meets endpoint in second atopic dermatitis trial; NeoTX lands USD 45 M series C; Five Prime Therapeutics’ pancreatic cancer a bust Visit Post
21 Thumbs down to NKTR-181, Lilly expands its insulin armamentarium Visit Post
22 Chronic Hand Eczema Market Analysis and Forecast Visit Post
23 Atopic dermatitis market and a Dupilumab dominance Visit Post
24 Atopic dermatitis market: Increasing prevalence and topical treatments Visit Post
25 World Psoriasis Day Visit Post
26 AngioDynamics acquires Eximo; MiroBio raises USD 33 M; Janssen submits sBLA for Stelara Visit Post
27 Psoriasis Pipeline: Upcoming Psoriasis Treatments Visit Post
28 Psoriasis Therapy Market Size  Visit Post
29 Generalized Pustular Psoriasis Market Visit Post
30 Acne Vulgaris Market Outlook Visit Post
31 Acute Bacterial Skin and Skin Structure Infections Emerging Therapies Visit Post
32 ABSSSI Current Therapeutic Market Visit Post
33 Recent Market Reports Visit Post
34 Peloton raises $150M; BiomX raises $32M; Abbott and Novo collaborate; Blaze Bioscience nets $5M Visit Post
35 Actinic Keratosis – A Warning Sign for Potential Skin Cancer Visit Post
36 Notizia Visit Post
37 Biologic Parallel – A Perky Future Ahead Visit Post
38 Notizia Visit Post
39 Idera's drug; CRISPR increase risk; Juvenescence grabbed USD 50M; AstraZeneca, Lilly terminates Visit Post
40 Business Cocktail Visit Post
41 NOTIZIA Visit Post
42 Business Cocktail Visit Post
43 Biohaven’s trial ; GSK integrates; FDA Approval; Phase III trial Visit Post
44 Actinic Keratosis – A Warning Sign for Potential Skin Cancer Visit Post
45 Vitiligo – High Unmet Need Indeed! Visit Post
46 Cancer, diabetes and eczema on list; AbbVie's Humira; Teva weighs $2B; Fresenius in buyout talks Visit Post
47 FDA grants approval; Sanaria receives fast-track designation; Sanofi and Regeneron’s next blockbuster; Allele receives NIH grant Visit Post
48 AstraZeneca’s new Asthma Drug Aces Phase III trial Visit Post
49 LAG-3 Antagonists, TIM-3 Antagonists; OX40 Agonists- Pipeline Insights, 2016 - A DelveInsight Report Visit Post
50 DelveInsight’s Dermatology based Gene Therapy Reports Visit Post